Cartesian Therapeutics (RNAC) Cash from Financing Activities (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Cash from Financing Activities data on file, last reported at $15.7 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 295.28% year-over-year to $15.7 million in Q1 2026; TTM through Mar 2026 was $15.6 million, a 86.67% decrease from a year earlier, with the FY2025 full-year figure at -$8.1 million, down 104.78% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $15.7 million, up from -$52000.0 in the prior quarter.
• Over the last five years, Cash from Financing Activities for RNAC reached as high as $124.5 million in Q3 2024 and fell as low as -$24.8 million in Q3 2023.
• Historically, Cash from Financing Activities has averaged $12.6 million across 5 years, with a median of $380500.0 in 2022.
• Across the five-year window, Cash from Financing Activities sank 4150.49% in 2023 and jumped 28779.87% in 2024, its largest moves.
• Year by year, Cash from Financing Activities stood at $612000.0 in 2022, then jumped by 2200.82% to $14.1 million in 2023, then sank by 94.44% to $783000.0 in 2024, then sank by 106.64% to -$52000.0 in 2025, then soared by 30236.54% to $15.7 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $15.7 million in Q1 2026, -$52000.0 in Q4 2025, and -$38000.0 in Q3 2025.